Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7444210 | 0.74 | — | — | |
| SCHEMBL28767093 | 0.70 | LMNA (0.32) | TSHRALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL4188563 | 0.69 | KDM4E (0.32) | TSHRALDH1A1 | |
| SCHEMBL10930583 | 0.69 | MMP1 (0.31) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL28310377 | 0.69 | TSHR (0.41) | TSHRALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL28542176 | 0.68 | MEN1 (0.37) | TSHRMAPK1MEN1KMT2A | |
| SCHEMBL8172810 | 0.68 | TSHR (0.32) | TSHR | |
| SCHEMBL2710782 | 0.67 | TSHR (0.39) | TSHRALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL17243242 | 0.67 | HCAR2 (0.33) | TSHR | |
| SCHEMBL28560912 | 0.67 | HCAR2 (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217063-B1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | VIRGINIA TECH INTELL PROP (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8558019-B2 | Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | ZAHAV BIOSCIENCES LLC | 2011-06-16 | — | — | US | disclosed |
| EP-2217063-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | Virginia Tech Intellectual Properties, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009062138-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144163-A1 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS | TUBB6, TUBB1, TUBB | TSHR 877/4885ALDH1A1 189/4885MAPK1 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.